What is Quantitative Transcriptome Analysis Market?
The transcriptome is the complete collection of all RNA molecules found in a single cell, a population of cells, or a living organism. The quantitative transcriptome analysis market is gaining traction as a method for drug development and cancer research. Quantitative transcriptome analysis is expected to become more common in the future as the human disease becomes more complex.
The market study is being classified by Type (Medical Instruments, Consumables and Services), by Application (Drug Discovery and Development, Cancer Research, Diagnosis and Disease Treatment) and major geographies with country level break-up.
Illumina, Inc (United States), F. Hoffmann-La Roche Ltd. (Switzerland), BGI Genomics (China), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Macrogen (South Korea), Agilent Technologies (United States), 10x Genomics (United States), Promega Corporation (United States), Bio-Rad Laboratories, Inc. (United States) and GE Healthcare (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fluidigm Corporation (United States) and Merck & Co., Inc. (United States).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Quantitative Transcriptome Analysis market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Quantitative Transcriptome Analysis market by Type, Application and Region.
On the basis of geography, the market of Quantitative Transcriptome Analysis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Research and Development Activities for Novel Cancer Therapeutic
- Rising Complex Human Disease
- Technical Progress in Medical Industry
- Ethical and Scientific concern of Transcriptome Analysis
- Higher Funding Allocations to the Drug Discovery
- Increasing Use of Biosimilars to Treat Severe Disease
- Insufficient Skilled Personnel
In March 2017, Lexogen, a transcriptomics and next generation sequencing company, announces the start of its RNA-Seq service, which focuses on gene expression profiling using Lexogen’s proprietary QuantSeq technology.
Key Target AudienceNew Entrants and Investors, Quantitative Transcriptome Analysis Providers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase